28
Participants
Start Date
July 25, 2019
Primary Completion Date
September 13, 2021
Study Completion Date
November 22, 2021
dextromethorphan HBr and quinidine sulfate
All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.
University of Florida, Gainesville
Phil Smith Neuroscience Institute at Holy Cross Hospital, Fort Lauderdale
Holy Cross Hospital, Florida
OTHER
ALS Association
OTHER
University of Florida
OTHER